INVESTOR RELATIONS
PARTNER WITH US IN CLOSING THE GENDER HEALTH GAP
HELP PIONEER A FUTURE WHERE HEALTH EQUITY IS A REALITY, AND THE GENDER HEALTHCARE GAP IS NO LONGER A BARRIER.
By addressing underserved needs in women's health, we are creating solutions that resonate with real experiences and empower people to lead healthier lives. Join us in shaping this impact-driven journey towards meaningful change.
For more information, please reach out to our Investor Relations Team at ir@meliodays.com.
INVEST AS A PROFESSIONAL INVESTOR
You have the opportunity to support a groundbreaking movement in women's health. By investing in Meliodays, you're backing a mission to address long-standing disparities in healthcare, particularly in menstrual health and pain management. We are at the forefront of Femtech innovation, with a data-driven approach and a deep understanding of the needs of women today.
THE PROBLEM
Over 1.4 billion people worldwide suffer from menstrual pain, with 20-30% experiencing pain severe enough to disrupt daily life. Despite its prevalence, menstrual pain is often dismissed, with the medical community historically underfunding research into female physiology. As a result, treatment options remain limited, and the economic impact is staggering, with the loss of up to 2 billion USD annually in the US alone. Addressing this issue is not only a health priority but a critical need for innovation and progress in women’s health.
IMPACT AND VISION
For too long, women's health has been ignored, with conditions like endometriosis and fibroids under-researched and under-treated. At Meliodays, we reject the flawed paradigm that women should simply accept their pain. Our vision is to create a world where health equity exists, where women are heard, and where innovative, research-backed solutions are accessible.
OUR SOLUTION
MelioOne is the world’s first intra-uterine device (IUD) designed to deliver pain medication instead of hormones. Using proven polymer-based technology, it releases a low, localized dose of medication directly at the source of pain, reducing inflammation without systemic side effects like those from prolonged NSAID use.
This unique combination of targeted drug delivery and NSAID efficacy makes MelioOne an innovative, non-hormonal solution to period pain, offering a safer alternative for those who cannot use hormonal IUDs or experience side effects from traditional pain medications.
DEVELOPMENTAL JOURNEY
MelioOne is in prototyping phase to test out the polymer-technology that enables the low and slow-release mechanism. We are currently on track with timeline projections and working towards the start of Pre-Clinical Trials by the fourth quarter this year. It will not be until 2029 that we can enter the market with a solution that has been proven safe and effective in clinical trials.